BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38510678)

  • 1. Bone metastasis in non-small-cell lung cancer: genomic characterization and exploration of potential targets.
    Gong J; Hu S; Shan Q; Qin J; Han N; Xie F; Lu H
    Ther Adv Med Oncol; 2024; 16():17588359241239293. PubMed ID: 38510678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036).
    Wang H; Ou Q; Li D; Qin T; Bao H; Hou X; Wang K; Wang F; Deng Q; Liang J; Zheng W; Wu X; Wang X; Shao YW; Mou Y; Chen L
    Cancer; 2019 Oct; 125(20):3535-3544. PubMed ID: 31287555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology and survival outcomes of synchronous and metachronous brain metastases: a retrospective population-based study.
    Jiang K; Parker M; Materi J; Azad TD; Kamson DO; Kleinberg L; Ye X; Rincon-Torroella J; Bettegowda C
    Neurosurg Focus; 2023 Aug; 55(2):E3. PubMed ID: 37527669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study.
    Bragstad S; Flatebø M; Natvig GK; Eide GE; Skeie GO; Behbahani M; Pedersen PH; Enger PØ; Skeie BS
    J Neurosurg; 2018 Jul; 129(1):71-83. PubMed ID: 28820304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.
    Huang RSP; Harries L; Decker B; Hiemenz MC; Murugesan K; Creeden J; Tolba K; Stabile LP; Ramkissoon SH; Burns TF; Ross JS
    Oncologist; 2022 Oct; 27(10):839-848. PubMed ID: 35598205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic and predictive role of hyponatremia in patients with advanced non-small cell lung cancer (NSCLC) with bone metastases.
    Rinaldi S; Santoni M; Leoni G; Fiordoliva I; Marcantognini G; Meletani T; Armento G; Santini D; Newsom-Davis T; Tiberi M; Morgese F; Torniai M; Bower M; Berardi R
    Support Care Cancer; 2019 Apr; 27(4):1255-1261. PubMed ID: 30406916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome.
    Mogenet A; Barlesi F; Besse B; Michiels S; Karimi M; Tran-Dien A; Girard N; Mazieres J; Audigier-Valette C; Locatelli-Sanchez M; Kamal M; Gestraud P; Hamza A; Jacquet A; Jimenez M; Yara S; Greillier L; Bertucci F; Planchard D; Soria JC; Bieche I; Tomasini P
    Lung Cancer; 2022 Jul; 169():31-39. PubMed ID: 35609409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in Genomic Alterations Between Brain Metastases and Primary Tumors.
    Dono A; Takayasu T; Yan Y; Bundrant BE; Arevalo O; Lopez-Garcia CA; Esquenazi Y; Ballester LY
    Neurosurgery; 2021 Feb; 88(3):592-602. PubMed ID: 33369669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Time Interval on Prognosis in Patients with Non-Small Cell Lung Cancer Brain Metastases After Metastases Surgery.
    Yang Z; Chen H; Jin T; Sun L; Li L; Zhang S; Wu B; Jin K; Zou Y; Sun C; Xia L
    World Neurosurg; 2023 Dec; 180():e171-e182. PubMed ID: 37704036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study.
    Zhang L; Hou X; Lu S; Rao H; Hou J; Luo R; Huang H; Zhao H; Jian H; Chen Z; Liao M; Wang X
    Lung Cancer; 2010 Jan; 67(1):114-9. PubMed ID: 19376608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impacts of extracranial metastasis on non-small cell lung cancer with brain metastasis: A retrospective study based on surveillance, epidemiology, and end results database.
    Wang M; Wu Q; Zhang J; Qin G; Yang T; Liu Y; Wang X; Zhang B; Wei Y
    Cancer Med; 2021 Jan; 10(2):471-482. PubMed ID: 33320433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
    Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
    J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases.
    Wang J; Liu Z; Pang Q; Zhang T; Chen X; Er P; Wang Y; Wang P; Wang J
    BMC Cancer; 2020 Sep; 20(1):837. PubMed ID: 32883221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world analysis of first-line afatinib in patients with
    Kim J; Jang TW; Choi CM; Kim MH; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH
    Transl Lung Cancer Res; 2023 Jun; 12(6):1197-1209. PubMed ID: 37425421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NFAT as a Biomarker and Therapeutic Target in Non-Small Cell Lung Cancer-Related Brain Metastasis.
    Peng L; Tao Y; Wu R; Su J; Sun M; Cheng Y; Xie Z; Mao J; Zhan X; Liu G
    Front Oncol; 2021; 11():781150. PubMed ID: 34917508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases.
    Luo D; Ye X; Hu Z; Peng K; Song Y; Yin X; Zhu G; Ji Q; Peng Y
    Tumour Biol; 2014 Mar; 35(3):2437-44. PubMed ID: 24197981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
    Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
    Front Immunol; 2021; 12():697298. PubMed ID: 34858389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic cranial irradiation in non-small cell lung cancer patients: who might be the candidates?
    Dimitropoulos C; Hillas G; Nikolakopoulou S; Kostara I; Sagris K; Vlastos F; Alchanatis M
    Cancer Manag Res; 2011; 3():287-94. PubMed ID: 21931502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas.
    Saâda-Bouzid E; Burel-Vandenbos F; Ranchère-Vince D; Birtwisle-Peyrottes I; Chetaille B; Bouvier C; Château MC; Peoc'h M; Battistella M; Bazin A; Gal J; Michiels JF; Coindre JM; Pedeutour F; Bianchini L
    Mod Pathol; 2015 Nov; 28(11):1404-14. PubMed ID: 26336885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.